Compare BIO-TECHNE Corp (TECH) vs iShares TIPS Bond ETF (TIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs iShares TIPS Bond ETF — how do they compare? BIO-TECHNE Corp trades at $72.46 (market cap $11.37B), while iShares TIPS Bond ETF trades at $104.7 (market cap $14.16B). The key difference: iShares TIPS Bond ETF is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while iShares TIPS Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 63 Days and iShares TIPS Bond ETF for 61 Days on average.
| TECH | TIP | |
|---|---|---|
Market Cap | $11.37B | $14.16B |
Volume | 3,153,511 | 1,695,817 |
Sector | Health | Fixed Income |
52-Week High | $72.61 | $112.20 |
52-Week Low | $43.31 | $103.98 |
Typical Hold Time | 63 Days | 61 Days |
Enterprise Value | $11.40B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
TIP trades at $104.24, showing minimal daily movement with a 0.06% gain. Technical indicators signal a bearish trend, while oscillators remain neutral. The ETF's financial ratios are not available in the provided data, limiting fundamental assessment. A dividend of $0.78 is scheduled for August 2026, indicating income potential amid current market volatility driven by rising bond yields and geopolitical tensions.
Outlook is cautious due to bearish technicals and macroeconomic pressures from high Treasury yields. The dividend offers a yield cushion, but investors face risks from bond market instability and inflationary concerns. Monitoring Federal Reserve policy and inflation data is critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About iShares TIPS Bond ETF
TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →
